| |
|
|
|
| Acute Appendicitis; Acute Cholecystitis; Diverticulitis (Meckel’s); Inflammatory Bowel Disease (Crohn’s); Duodenal Ulcer; Intestinal Obstruction ... |
|
|
|
|
| Crohn’s disease (CD) and ulcerative colitis (UC) are the 2 major forms of idiopathic .... Indicated in fisulizing crohns, refractory CD and refractory UC |
|
|
|
|
| Myasthenia gravis. Crohn’s disease. Grave’s disease. Type 1 Diabetes mellitus. Rheumatoid arthritis. Psoriasis. Scleroderma. Systemic lupus erythematosus … |
|
|
|
|
| Similar risk for colorectal cancer in Crohn disease and in ulcerative colitis.Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk ... |
|
|
|
|
| Crohn’s Disease and Ulcerative Colitis are chronic, progressive inflammatory bowel diseases (IBD) characterised by periods of exacerbation and remission. ... |
|
|
|
|
| Smoking; Appendectomy. NOD2 mutations predispose to the development. of Crohn’s disease. Immunologic Hypothesis of IBD. Inflammatory bowel disease is due to ... |
|
|
|
|
| from gene to therapy. Prof Jean-Pierre Hugot. Hopital Robert Debré Gene therapy (in the future?) Pharmacogenetics; Drug discovery (disease mechanisms) |
|
|
|
|
| Inflammatory bowel disease (IBD). Crohn’s disease (CD); Ulcerative colitis (UC). Metabolic syndrome; Genetic predisposition to both conditions ... |
|
|
|
|
| Rheumatoid Arthritis; Systemic Lupus Erythematosus; Polymyositis; Polyarteritis Nodosa. Inflammatory Bowel Disease. Ulcerative Colitis; Crohn’s Disease |
|
|
|
|
| Inflammatory mediators:. Cytokines, chemokines. and lipidsNOD2 gene increase susceptibility to Crohn’s disease (a form of inflammatory bowel disease) ... |
|
|
